Cargando…

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. CDK4/6 controls pathway downstream of Her2, Inhibition of these kinases could represent an important therapeutic approach to augment the effectiveness of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witkiewicz, Agnieszka K., Cox, Derek, Knudsen, Erik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162138/ https://www.ncbi.nlm.nih.gov/pubmed/25221644

Ejemplares similares

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
por: Franco, Jorge, et al.
Publicado: (2014)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
por: Franco, Jorge, et al.
Publicado: (2020)

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
por: Kumarasamy, Vishnu, et al.
Publicado: (2019)

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
por: Knudsen, Erik S., et al.
Publicado: (2019)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
por: Kuchukulla, Ratnakar Reddy, et al.
Publicado: (2022)

The Retinoblastoma Tumor Suppressor Pathway Modulates the Invasiveness of ErbB2 Positive Breast Cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2013)

The emerging role of CDK4/6i in HER2-positive breast cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2019)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
por: Ni, Jing, et al.
Publicado: (2022)

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
por: Wander, Seth A, et al.
Publicado: (2022)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
por: Sun, Bowen, et al.
Publicado: (2019)

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
por: Matutino, Adriana, et al.
Publicado: (2018)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

CDK4/6 inhibition is more active against the glioblastoma proneural subtype
por: Li, Ming, et al.
Publicado: (2017)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

CDK4/6 inhibition in breast cancer: current practice and future directions
por: Pernas, Sonia, et al.
Publicado: (2018)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
por: Bisi, John E., et al.
Publicado: (2017)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro
por: Wang, Hongqian, et al.
Publicado: (2019)

CDK12: A Potent Target and Biomarker for Human Cancer Therapy
por: Liang, Shujing, et al.
Publicado: (2020)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2
por: Moradimotlagh, Atieh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s9dlj0k8q146gsttiml1v372kf